New Gene May Intensify Breast Cancer Growth

August 13, 1997

Bethesda, MD - Scientists in the National Human Genome Research Institute (NHGRI) at the National Institutes of Health (NIH) have discovered a new gene that is pivotal to a crucial metabolic pathway linked to the growth and progression of human breast cancer. The gene appears to be expressed at abnormally high levels in tumor cells of most breast cancer patients, more than half of cases examined so far. The researchers report their findings in the August 15 issue of Science.

In many cancers, but especially breast cancer, tumor cells accumulate extra copies of genes that give the cancer a growth advantage. The new gene is one such amplified gene. The gene, previously unknown, is linked to the estrogen response pathway. The scientists expect further study of the gene to help reveal the basic biology of tumor cells, especially those responsive to steroid hormones. This group of diseases includes not just breast and ovarian cancer, but prostate cancer as well.

The NHGRI researchers found the gene, which they call AIB1 (amplified in breast cancer-1), by searching the long arm of chromosome 20 for genes whose expression and copy number are elevated in breast cancer. The gene is expressed at lower levels in normal human tissue. AIB1 is the most recently identified member of a gene family known as SRC-1 (steroid receptor coactivator), all of which interact with genes for steroid hormone receptors, ultimately enhancing tumor cell growth.

"It's another example where information that we have about other members of this gene family allows us to infer that this may be very important in breast biology, regulating not just steroid growth response but possibly other growth response pathways. It could eventually be a target for therapeutics. It will certainly be a target for significant additional biologic studies to understand its action," said Dr. Paul Meltzer, the senior author of the paper, and a faculty member of the NHGRI's Division of Intramural Research, at the NIH.

The finding is too new to have an immediate impact on breast cancer therapies. "At this early stage, we're really thinking more in terms of the fundamental cell biology of breast cancer. We think this gene is probably part of the engine that drives the growth of some breast cancers, and we're trying to understand how that works," said Dr. Jeffrey Trent, a co-author of the paper and head of the NHGRI laboratory where the gene was cloned.

The researchers have also begun to design the first clinical studies using the gene as a marker to find out how it affects the course of breast cancer. "Do the patients who make a lot of the message from this gene respond differently to therapy, do they have a different clinical outcome, are their tumors different, do they develop at a different age or at a different rate" We don't have answers to any of those questions yet, but we are actively seeking the answers," said Trent.

"A lot is known about how steroid receptors work, but the wiring of how they send their signals has been imperfectly understood. There are a lot of different genes which seem to be part of this system. We suspect that this one is a particularly important part of the wiring system in the breast cancer cell that transmits the signal from steroids like estrogen that says 'grow,'" Meltzer said. "It gives us a important new window into the cell biology of breast cancer that emphasizes the importance of this particular kind of gene to the growth of cancer cells in a significant number of patients. And that's going to be an extremely interesting thing to investigate."

Previously, other genes found to be amplified in breast cancer have led to clinical tests and trials of therapy. AIB1 may turn out to be a new candidate for similar development, Meltzer noted.

NHGRI oversees the NIH's role in the Human Genome Project, an international research effort to develop tools for gene discovery.
-end-

Media Contacts:
Jeff Witherly (301) 402-8564
Galen Perry (301) 402-3035

Additional information will be available following embargo on the NHGRI web site, located at: http://www.nhgri.nih.gov/

NIH/National Human Genome Research Institute

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.